CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors

Irene M. Min, Enda Shevlin, Yogindra Vedvyas, Marjan Zaman, Brian Wyrwas, Theresa Scognamiglio, Maureen D. Moore, Weibin Wang, Susan Park, Spencer Park, Suraj Panjwani, Katherine D. Gray, Andrew B. Tassler, Rasa Zarnegar, Thomas J. Fahey, Moonsoo M. Jin

Research output: Contribution to journalArticlepeer-review

81 Scopus citations

Abstract

Purpose: Poorly differentiated thyroid cancer and anaplastic thyroid cancer (ATC) are rare yet lethal malignancies with limited treatment options. Many malignant tumors, including papillary thyroid cancer (PTC) and ATC, are associated with increased expression of ICAM-1, providing a rationale for utilizing ICAM-1-targeting agents for the treatment of aggressive cancer. We developed a third-generation chimeric antigen receptor (CAR) targeting ICAM-1 to leverage adoptive T-cell therapy as a new treatment modality. Experimental Design: ICAM-1 CAR T cells were applied to multiple malignant and nonmalignant target cells to investigate specific target cell death and "off-tumor" toxicity in vitro. In vivo therapeutic efficacy of ICAM-1 CAR T cells was examined in ATC mouse models established from a cell line and patient-derived tumors that rapidly develop systemic metastases. Results: ICAM-1 CAR T cells demonstrated robust and specific killing of PTC and ATC cell lines in vitro. Interestingly, although certain ATC cell lines showed heterogeneous levels of ICAM-1 expression, addition of cytotoxic CAR T cells induced increased ICAM-1 expression such that all cell lines became targetable. In mice with systemic ATC, a single administration of ICAM-1 CAR T cells mediated profound tumor killing that resulted in long-term remission and significantly improved survival. Patient-derived ATC cells overexpressed ICAM-1 and were largely eliminated by autologous ICAM-1 CAR T cells in vitro and in animal models. Conclusions: Our findings are the first demonstration of CAR T therapy against both a metastatic, thyroid cancer cell line and advanced ATC patient-derived tumors that exhibit dramatic therapeutic efficacy and survival benefit in animal studies.

Original languageEnglish (US)
Pages (from-to)7569-7583
Number of pages15
JournalClinical Cancer Research
Volume23
Issue number24
DOIs
StatePublished - Dec 15 2017

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors'. Together they form a unique fingerprint.

Cite this